REG - Feedback PLC - Trading Update

FeedbackAnnouncement

18/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR9970La&default-theme=true

RNS Number : 9970L  Feedback PLC  18 December 2025

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to Article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended. Upon the publication of this announcement
via a Regulatory Information Service, this inside information is now
considered to be in the public domain.

 

Feedback plc

 

Trading Update

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, provides a trading update for the six months to 30
November 2025 (the "Period").

 

Revenue for the Period is expected to be c. £0.4m (H1 2025: £0.4m). Cash
outlook remains in line with expectations and the Company continues to have
sufficient cash runway through to mid-2027.

 

The backdrop is stabilising after last year's uncertainty and disruption
across the NHS. During the Period there has been increased focus from policy
makers and NHS management on the role of technology and digitisation in
reducing NHS waiting times, combined with moves towards neighbourhood
healthcare. This is supported by commitments to increase NHS technology spend.

 

Bleepa is well positioned given its proven capabilities and capacity to
address analogue to digital and facilitate hospital to community, combined
with its ability to help reduce waiting lists. As last year's disruption
passes and given the increasing focus on technology and the flexibility of the
Company's solutions, management expects that sales momentum could build around
the next tax year, with the Company positioned to scale quickly and
effectively.

 

Dr Tom Oakley, CEO of Feedback plc, said: "The 10-year plan and direction of
travel of the NHS are clearly aligned with the solutions we provide. Spending
Review funding is due to be released to the NHS frontline for 2026/27, and we
believe that this combined with an increasing recognition of the role of
technology in healthcare will drive a new phase of commercialisation for
Feedback."

 

 

--Ends--

Enquiries:

 

 Feedback plc                                +44 (0) 20 3997 7634

 Tom Oakley, CEO                             IR@fbk.com (mailto:IR@fbk.com)

 Emma Oswick, CFO

 Panmure Liberum Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                            Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                             (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                        07748 325 236 or 07407 020 470

 

About Feedback plc

 

Feedback plc liberates the data and knowledge from multiple healthcare IT
systems and delivers better workflow to enable clinicians to communicate,
collaborate and provide the best healthcare for their patients. We connect
care settings with diagnostic and other relevant data to drive better, faster,
safer decision that improve outcomes for patients.

 

By linking different clinical systems together into a seamless view of the
patient, we can streamline patient pathways and deliver a digital health and
diagnostics record across multiple care providers.

 

Bleepa® is our communication and collaboration platform that displays
clinical results at a certified and regulated quality, which enables
multi-disciplinary team working and diagnostic-enhanced advice and guidance.
CareLocker® is our patient-facing platform that gives patients access and
control over their diagnostic and other clinical data.

 

The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.

 

https://feedbackmedical.com/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__feedbackmedical.com_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lwwmT1lSfgELFLcwvlJQ2ZXDKcVbkQyitKwD17cChBQ&m=oBFM-ht-5vvdSXufzCuQmLfPWIaMcFGcjFY8Tl7Z-dsq0iW8FbXgExGw9gLP3va-&s=kayb21_5OhwDnHa1pJnJQjB1999VQgQynAFl7rWXro4&e=)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBUBDDXXBDGUR



            Copyright 2019 Regulatory News Service, all rights reserved